International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

pakistan journal of pharmaceutical sciences

BMC infectious diseases

journal of peptide science : an official publication of the european peptide society

Microbial pathogenesis

Environmental monitoring and assessment

The International journal on drug policy

mucosal immunology

hepatology international

journal of viral hepatitis

Journal of the American Academy of Child and Adolescent Psychiatry

nature microbiology

journal of clinical and experimental neuropsychology

Hospital pediatrics

viral immunology

the malaysian journal of pathology

Current HIV/AIDS reports

world journal of hepatology

[1] Strategies to manage hepatitis C virus infection disease burden - volume 3.

[2] The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

[3] Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.

[4] Effect of phenological stages on nutritional assessment of ten plant species in Tehsil Takht-e-Nasrati, District Karak, Pakistan.

[5] Monitoring of Coliforms and chlorine residual in water distribution network of Rawalpindi, Pakistan.

[6] Surveillance and impact of occult hepatitis B virus, SEN virus, and Torque teno virus in Egyptian hemodialysis patients with chronic hepatitis C virus infection.

[7] The emergence of microbiome centres.

[8] Possible Association of Elevated Plasma Levels of Growth Arrest-Specific Protein 6 and the Soluble Form of Tyrosine Kinase Receptor Axl with Low Hepatitis C Viral Load in Patients with Type 2 Diabetes Mellitus.

[9] Cellulitis in human brucellosis: An atypical presentation.

[10] Antigen discovery unveils resident memory and migratory cell roles in antifungal resistance.

[11] Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence.

[12] Improving the aqueous solubility of HCV-E2 glycoprotein epitope mimics by cyclization using POLAR hinges.

[13] Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.

[14] Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.

[15] prevalence of hepatitis c virus infection and associated factors among male illicit drug users in cuiabá, mato grosso, brazil

[16] anti-hcv prevalence and risk factors analysis in pregnant women in central brazil

[17] inhibitors of the hepatitis c virus polymerase; mode of action and resistance

[18] seroprevalence of human herpesvirus 8 and hepatitis c virus among drug users in shanghai, china

[19] distinct immunoregulatory cytokine pattern in egyptian patients with occult hepatitis c infection and unexplained persistently elevated liver transaminases

[20] characteristic morphological signs of the brain damage during chronic hepatitis c virus infection identified in autopsy samples

[21] carpal tunnel syndrome in hiv-positive patients coinfected with hcv

[22] inhibition of hepatitis c virus replication and viral helicase by ethyl acetate extract of the marine feather star alloeocomatella polycladia

[23] role of t-helper 9 cells in chronic hepatitis c-infected patients

[24] the exposure rate to hepatitis b and c viruses among medical waste handlers in three government hospitals, southern ethiopia

[25] c-myc—making liver sick: role of c-myc in hepatic cell function, homeostasis and disease

[26] hepatitis c virus as cause of fulminant hepatitis-sequence analysis of the 5’ nontranslated region

[27] hgv-hcv/hbv co-infection in india: a pilot study

[28] mexican consensus on the diagnosis and management of hepatocellular carcinoma

[29] preclinical development and production of virus-like particles as vaccine candidates for hepatitis c

[30] hepatitis c virus and non-hodgkin’s lymphomas: a minireview

[31] occurrence and recurrence of hepatocellular carcinoma were not rare events during phlebotomy in older hepatitis c virus-infected patients

[32] evaluaciÓn de algunos factores de riesgo de contraer hepatitis c en pacientes hemodializados

[33] prevalence of hepatitis b and hepatitis c virus co-infection in india: a systematic review and meta-analysis

[34] a cross section study to determine the prevalence of antibodies against hiv infection among hepatitis b and c infected individuals

[35] the dual role of exosomes in hepatitis a and c virus transmission and viral immune activation

[36] hepatitis c virus genie: a web 2.0 interpretation and analytics platform for the versant hepatitis c virus genotype line probe assay version 2.0

[37] alta prevalência do genótipo 1 em portadores de hepatite c crônica em belo horizonte, mg high prevalence of genotype 1 in individuals with hepatitis c in belo horizonte, mg

[38] reflexões sobre o adoecer e mudanças dietéticas durante a assistência nutricional em pacientes com hepatite c reflections about getting sick and dietetic changes during nutritional assistance with hepatitis c patients

[39] designing a b cell-based vaccine against a highly variable hepatitis c virus

[40] comparison of fibrotest-actitest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis b and c

[41] hyperbilirubinemia without transaminitis during combined therapy with daclatasvir and asunaprevir

[42] <title language="por">hepatitis b and c in the hemodialysis unit of tocantins, brazil: serological and molecular profiles

[43] helicobacter pylori serology in relation to hepatitis c virus infection and il28b single nucleotide polymorphism

[44] molecular characterization of the rna-binding protein quaking-a in megalobrama amblycephala: response to high-carbohydrate feeding and glucose/insulin/glucagon treatment

[45] recent advances in hepatitis c virus cell entry

[46] morphogenesis of infectious hepatitis c virus particles

[47] Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination.

[48] Editorial: One Reason Why Not.

[49] Continuing Medical Education in an On-Demand World: Is Podcasting the Netflix of Medical Education?

[50] direct anti-hcv agents

[51] Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.

[52] Direct-acting antiviral agents for HCV infection affecting people who inject drugs - Nature Reviews Gastroenterology & Hepatology

[53] Molecular Diagnosis of Hepatitis C Viruses; Technologies and Their Clinical Applications

[54] Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

[55] Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.

[56] Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach.

[57] Sofosbuvir&ndash;daclatasvir improves hepatitis C virus&ndash;induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[58] Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

[59] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[60] Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

[61] Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

[62] Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

[63] Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

[64] Sofosbuvir&ndash;daclatasvir improves hepatitis C virus&ndash;induced mixed cryoglobulinemia: Upper Egypt experience

[65] Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

[66] Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-na&iuml;ve hepatitis C genotype 1b-infected patients in western China

[67] Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

[68] Influence of host resistance on viral adaptation: hepatitis C virus as a case study

[69] New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

[70] Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

[71] Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

[72] Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

[73] Sofosbuvir&ndash;daclatasvir improves hepatitis C virus&ndash;induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[74] Sofosbuvir&ndash;daclatasvir improves hepatitis C virus&ndash;induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[75] Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

[76] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[77] Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

[78] Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

[79] Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

[80] Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

[81] Sofosbuvir&ndash;daclatasvir improves hepatitis C virus&ndash;induced mixed cryoglobulinemia: Upper Egypt experience

[82] Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

[83] Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-na&iuml;ve hepatitis C genotype 1b-infected patients in western China

[84] Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

[85] Influence of host resistance on viral adaptation: hepatitis C virus as a case study

[86] New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

[87] Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

[88] Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

[89] Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

[90] Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia.

[91] The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015.

[92] Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: a cohort study.

[93] The new Xpert HCV viral load real-time PCR assay accurately quantifies hepatitis C virus RNA in serum and whole-blood specimens

[94] Prevalence of mixed hepatitis C virus (HCV) genotypes among recently diagnosed dialysis patients with HCV infection

[95] Prevalence and distribution of hepatitis C virus genotypes in Galicia during the period 2000-2015

[96] Molecular epidemiology of hepatitis C virus in Cambodia during 2016–2017

[97] The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses

[98] Epidemiology of Hepatitis C Virus in Bangladeshi General Population

[99] Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

[100] Alchemy: A web 2.0 real-time quality assurance platform for human immunodeficiency Virus, hepatitis C Virus, and BK Virus quantitation assays

[101] Hepatitis C virus elimination in Indonesia: Epidemiological, cost, and cost-effectiveness modelling to advance advocacy and strategic planning.